Bausch + Lomb

BLCO

Market cap $5.35B

Investors looking for stocks in the Medical Services sector might want to consider either Bausch + Lomb (BLCO) or Danaher (DHR). But which of these two stocks offers value investors a better bang for their buck right now?

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter financial results on Wednesday, Oct. 29, 2025. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the c.

Bausch + Lomb Corporation (NYSE:BLCO ) Bausch + Lomb Corporation Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:45 AM EDT Company Participants Brenton L. Saunders - CEO & Chairman Osama Eldessouky - Executive VP & CFO Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Presentation Patrick Wood MD of Equity Research Good morning.

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of ASANA gas permeable (GP) lenses. ASANA offers eye care professionals a versatile, all-in-one comprehensive GP portfolio, featuring spherical, aspheric, toric, multifocal, multifocal toric, reverse geometry and keratoconic contact lenses. “Many still prefer rigid gas permeable contact lenses fo.

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the Amended and Restated Director Appointment and Nomination Agreement, dated as of June 21, 2022, by and among the company and Mr. Carl C. Icahn and certain of his affiliates, terminated pursuant to its terms when the Icahn group's net long position in the common shares of Bausch + Lomb's parent company, B.

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that members of its management team will participate in two investor conferences in September: J.P. Morgan European Leveraged Finance Conference September 3, 2025, London, U.K. Morgan Stanley Global Healthcare Conference September 8, 2025, 7:45 a.m. ET, New York, NY Executive Vice President and Chief Financial O.

Bausch Lomb (BLCO) Q2 Revenue Rises 5%

Bausch + Lomb Corporation (NYSE:BLCO ) Q2 2025 Earnings Conference Call July 30, 2025 8:00 AM ET Company Participants Brenton L. Saunders - CEO & Chairman George Gadkowski - Corporate Participant Osama A.

Although the revenue and EPS for Bausch + Lomb (BLCO) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.13 per share a year ago.